For the fourth year running, Orange Biomed is heading back to the Diabetes Technology Meeting — this time with fresh data on its pocket-sized A1C meter and a clearer path toward U.S. availability.
Company to present new A1C research and join the Startup Showcase in its fourth consecutive year at the meeting
Our goal is to make A1C testing more accessible at home and help people manage their diabetes more conveniently.”— Yeaseul Park, CEO of Orange Biomed
Also worth a look: Mitolyn, Built Around the Purple Peel Exploit, has been Launched, Designed to Enhance Mitochondrial Health & Manage Weight and Out Today: “My Favorite Things” by Award-winning Vocalist Nicole Henry.
WASHINGTON, D.C., WA, UNITED STATES, October 23, 2026 /EINPresswire.com/ — Orange Biomed, a diabetes technology company developing a pocket-sized HbA1c (A1C) meter based on microfluidic single-cell analysis, today announced that it will participate in the 26th Annual Diabetes Technology Meeting (DTM 2026), taking place Oct. 27-29 at the Hyatt Regency Crystal City in Washington, D.C. At the meeting, the company will present a scientific poster and take part in the Startup Showcase.
Co-hosted by the American Diabetes Association® (ADA) and the Diabetes Technology Society (DTS), DTM brings together researchers, clinicians and companies working on new approaches to diabetes care.
At the poster session, Orange Biomed will present its abstract titled "A Pump-Free Microfluidic Sensor for Highly Repeatable HbA1c Monitoring via Flow-Normalized RBC Velocity Variability." The study builds on the company's repeatability research presented as a Late-Breaking Poster at the ADA's 86th Scientific Sessions in June 2026.
The company's OBM rapid A1c is a reusable meter that measures A1C from a single 5 µL fingerstick blood sample and is designed to deliver results in five minutes. Conventional A1C tests, typically performed in laboratories or clinics, measure glycated hemoglobin biochemically using protein reagents. The OBM rapid A1c instead uses a proprietary microfluidic single-cell analysis platform that physically measures the characteristics of individual red blood cells. Because this approach does not rely on biochemical protein measurement, it is less affected by interference from hemoglobin variants. Its reagent-free cartridges can be stored and shipped at room temperature, and the meter requires no recalibration.
"DTM has been a regular stop for us since 2023, and the conversations we have here continue to shape our work," said Yeaseul Park, CEO of Orange Biomed. "At DTM 2026, we look forward to introducing our microfluidic technology to clinicians, researchers and industry partners who can help us bring it to the people who need it most. Our goal is to make A1C testing more accessible at home and help people manage their diabetes more conveniently."
Now attending DTM for the fourth consecutive year, Orange Biomed is accelerating its entry into the medical device market. The company earned ISO 13485 certification for its quality management system in September and is preparing a 510(k) submission to the U.S. FDA for potential over-the-counter clearance of the OBM rapid A1c.
Event Details:
- Event: 26th Annual Diabetes Technology Meeting (DTM 2026)
- Dates: Oct. 27-29, 2026
- Venue: Hyatt Regency Crystal City, Washington, D.C.
- Poster Session: Tuesday, Oct. 27, 2026, 6:35 p.m. EDT — Slot #26
- Poster Title: "A Pump-Free Microfluidic Sensor for Highly Repeatable HbA1c Monitoring via Flow-Normalized RBC Velocity Variability"
- Startup Showcase: Wednesday, Oct. 28, 2026, 4:35-6:35 p.m. EDT
Youra Park
Orange Biomed
Visit us on social media:
LinkedIn
Why it matters: If cleared by the FDA, a reagent-free, room-temperature-stable A1C meter could shift routine diabetes monitoring out of clinics and into homes, reducing barriers for millions who need frequent testing. Orange Biomed’s steady presence at DTM signals it is moving from research traction toward commercial reality.
